SteriCoat Corporation is a venture-backed biotechnology company developing medical devices incorporating the first implantable and permanently antimicrobial surface technology. The intellectual property comes from the MIT labs of Prof. Robert Langer and Prof. Greg Stephanopoulos, and part of this scientific research was featured in Nature.  

The company targets both purchasers and the medical user:

• Our value proposition to purchasers is to reduce the likelihood of infection, the cost of which usually comes out of a hospital’s bottom line. 

• Our value proposition to medical users is to improve patient health and reduce liability without requiring a change in practices. 

SteriCoat Corporation earned early technology and business model validation by winning entrepreneurial competitions at MIT, Harvard, Rice, Oxford, and Cambridge Universities in 2006.  This Cambridge, MA firm is headquartered in Kendall Square and has seven full-time employees.  

The company’s Chairman is Scott Rocklage, PhD, who is a partner at 5AM Ventures. Dr. Rocklage was the co-founder and CEO of Cubist Pharmaceuticals (NASDAQ: CBST).